With this zoomed-in view, the Abramson Family Cancer Research Institute (AFCRI) lab of Celeste Simon, PhD, and postdoctoral fellow, T.S. Karin Eisinger-Mathason PhD, report in Cancer Discovery about the potential of the collagen-modifying enzyme PLOD2 as a new therapeutic target for the treatment of metastatic undifferentiated pleomorphic sarcoma.
In an online video series, Florie Charles, a doctoral student at the University of California at San Francisco, and founder of Youreka Science, simply uses a white board and colored markers (and occasionally a small cut out mouse -- animal, not computer peripheral) to explain findings from recent papers in an accessible, fresh, and engaging way. One of her newest videos happens to feature a recent publication from the lab of Garret FitzGerald, MD, FRS, director of Penn Medicine's Institute of Translational Medicine and Therapeutics.
To show its gratitude to all laboratory professionals, the department of Pathology and Laboratory Medicine celebrated Medical Laboratory Professionals Week April 22-26, with a host of activities, such as Phillies Night, in appreciation of all the hard work and dedication of the hundreds of staff and faculty members working in more than 30 different laboratories across the Penn campus.
In early April, Penn Medicine hosted a fast-paced lightning round of presentations highlighting new and emerging technology being used inside and outside the Health System that may help patients and medical professionals alike. “Connected health” is about continuous sensing and monitoring to enable early detection, diagnosis and intervention, and improving outcomes at lower cost. Alternating between internal and external projects, the presenters brought their best ideas and applications to share, explaining how these new devices fit within the existing health care system and, in some cases, how they stretch the boundaries and may change the way healthcare is delivered.
“We Found a Change In Your DNA And We Don’t Know What it Means” – Questions and Challenges in the Era of Massively Parallel Gene Sequencing
Women who develop breast cancer while they’re young are often searching for answers about the cause for their disease or what they can do to improve their chances of being cured. While an increasing number of large genetic testing panels promise to scrutinize their DNA to uncover clues, a team of researchers from the Perelman School of Medicine and the Abramson Cancer Center has found that those powerful tests tend to produce more questions than they answer.
Penn Medicine will play a starring role in the Philadelphia Science Festival again this year. The Festival is a citywide collaboration showcasing science and technology every April. This year it runs from April 19 - 28, 10 days to celebrate the region’s strengths in science and technology, bringing together more than 100 partners from academia to museums to restaurants.
Cover image via TIME.com This week’s TIME magazine makes an eye-catching, bold proclamation. HOW TO CURE CANCER, the cover reads, with a subhead previewing the story contained inside: “Yes, it’s now possible – thanks to new cancer dream teams that are delivering better results faster.” Much of that team science...
To celebrate February as American Heart Month, the News Blog is highlighting some of the latest heart-centric news and stories from all areas of Penn Medicine. “I know this sounds like a cliché, but one of the main reasons I’m interested in learning about the genetic basis of heart...
In December and early January, years of neurological research unfolded in a few weeks time as papers published the work of Penn researchers and were able to deepen our understanding of a variety of conditions, both rare and common, hopefully getting closer to refining or finding effective treatments as a result.
Nathan Francis Mossell, MD, the first black student in Penn’s School of Medicine, received his medical degree in 1882. On his first day, he later wrote, he was “accompanied by a storm of protest” as his fellow incoming students sounded their displeasure. “I was not perturbed in the least,” wrote...
A “Modest Proposal:” Spreading the Wealth from Intellectual Property to Encourage New Players in Drug Development
Garret FitzGerald, MD, chair of the Department of Pharmacology and Director of the Institute for Translational Medicine & Therapeutics, Perelman School of Medicine at the University of Pennsylvania, has long said the current drug-development system in the United States is in need of change, “representing an unsustainable model.” He suggests...
Greg Sonnenberg, PhD, research associate in the Division of Gastroenterology and the Institute for Immunology, is one of 14 early-career scientists supported this year with an NIH Director's Early Independence Award. These support exceptional early-career scientists to move directly into independent research positions by essentially omitting the traditional post-doctoral training period.
This summer, Garret FitzGerald, MD, chair of the Institute for Translational Medicine and Therapeutics (ITMAT), testified at a briefing on the Hill organized by American Association for the Advancement of Science that the current drug-development system in the United States is flawed and in need of change.
Vladimir R. Muzykantov, MD, PhD, professor of Pharmacology and Medicine, at the Perelman School of Medicine, is devising a recombinant version of thrombomodulin -- a natural anticoagulant present in human blood vessels -- that can be injected in the bloodstream of animals, where it binds to RBCs and circulates for a long time as a prodrug that gets activated at sites of thrombosis, preventing closing up of blood vessels.